Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
News Item
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758384/
http://dx.doi.org/10.1007/s40278-022-08680-z
_version_ 1784632889313329152
collection PubMed
description
format Online
Article
Text
id pubmed-8758384
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-87583842022-01-14 Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant Reactions Weekly News Item Springer International Publishing 2022-01-15 2022 /pmc/articles/PMC8758384/ http://dx.doi.org/10.1007/s40278-022-08680-z Text en © Springer International Publishing AG 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle News Item
Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant
title Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant
title_full Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant
title_fullStr Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant
title_full_unstemmed Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant
title_short Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant
title_sort casirivimab/imdevimab lack of efficacy against covid-19 omicron variant
topic News Item
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758384/
http://dx.doi.org/10.1007/s40278-022-08680-z

Ejemplares similares